Vincerx Pharma, Inc. (NASDAQ:VINC) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. lessened its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 29.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 674,193 shares of the company’s stock after selling 280,634 shares during the quarter. Point72 Asset Management L.P. owned about 2.27% of Vincerx Pharma worth $546,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Vincerx Pharma by 29.9% during the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock worth $3,375,000 after buying an additional 153,575 shares during the period. Marshall Wace LLP grew its stake in shares of Vincerx Pharma by 359.1% during the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock valued at $266,000 after acquiring an additional 256,967 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Vincerx Pharma during the second quarter worth about $1,610,000. Institutional investors and hedge funds own 44.02% of the company’s stock.

Vincerx Pharma Stock Performance

Shares of VINC opened at $0.73 on Friday. Vincerx Pharma, Inc. has a one year low of $0.51 and a one year high of $9.37. The stock has a 50-day moving average price of $0.69 and a 200 day moving average price of $1.27. The company has a market capitalization of $21.66 million, a P/E ratio of -0.41 and a beta of 1.49.

Vincerx Pharma (NASDAQ:VINC) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.12. As a group, equities research analysts forecast that Vincerx Pharma, Inc. will post -0.49 earnings per share for the current fiscal year.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.